Combretastatin A2Alternative Names: Combretastatin-A2; CS-A2
Latest Information Update: 28 Nov 2007
At a glance
- Originator National Cancer Institute (USA)
- Class Antineoplastics; Combretastatins; Stilbenes
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 28 Oct 1997 No-Development-Reported for Cancer in USA (Unknown route)